NxStage Medical Inc. (NASDAQ:NXTM) was up 5.7% during trading on Tuesday . The company traded as high as $25.49 and last traded at $25.42, with a volume of 581,822 shares changing hands. The stock had previously closed at $24.05.

A number of equities research analysts have recently commented on NXTM shares. BTIG Research reaffirmed a “buy” rating and issued a $27.00 price objective on shares of NxStage Medical in a research report on Tuesday, June 7th. Northland Securities raised NxStage Medical from a “market perform” rating to an “outperform” rating and set a $25.00 price objective for the company in a research report on Tuesday, June 28th. Piper Jaffray Cos. reaffirmed an “overweight” rating and issued a $21.00 price objective on shares of NxStage Medical in a research report on Tuesday, May 17th. Zacks Investment Research raised NxStage Medical from a “hold” rating to a “buy” rating and set a $24.00 price objective for the company in a research report on Wednesday, July 6th. Finally, Jefferies Group lifted their price objective on NxStage Medical from $24.00 to $27.00 and gave the company a “buy” rating in a research report on Friday, August 5th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $26.43.

The company’s market capitalization is $1.62 billion. The firm has a 50 day moving average of $22.11 and a 200 day moving average of $18.11.

NxStage Medical (NASDAQ:NXTM) last announced its quarterly earnings data on Thursday, August 4th. The medical device company reported ($0.03) EPS for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.01. During the same quarter last year, the company posted ($0.08) EPS. The company had revenue of $92.20 million for the quarter, compared to analyst estimates of $89.44 million. NxStage Medical’s revenue was up 14.8% on a year-over-year basis. On average, analysts expect that NxStage Medical Inc. will post ($0.12) EPS for the current fiscal year.

Several large investors recently made changes to their positions in NXTM. Wells Fargo & Company MN increased its stake in shares of NxStage Medical by 6.5% in the fourth quarter. Wells Fargo & Company MN now owns 1,450,307 shares of the medical device company’s stock worth $31,777,000 after buying an additional 88,286 shares during the period. Jennison Associates LLC increased its stake in shares of NxStage Medical by 32.9% in the fourth quarter. Jennison Associates LLC now owns 1,395,174 shares of the medical device company’s stock worth $30,568,000 after buying an additional 345,394 shares during the period. New York State Common Retirement Fund increased its stake in shares of NxStage Medical by 4.1% in the fourth quarter. New York State Common Retirement Fund now owns 76,493 shares of the medical device company’s stock worth $1,676,000 after buying an additional 3,000 shares during the period. Rhumbline Advisers increased its stake in shares of NxStage Medical by 8.3% in the fourth quarter. Rhumbline Advisers now owns 68,426 shares of the medical device company’s stock worth $1,499,000 after buying an additional 5,240 shares during the period. Finally, Morgan Stanley increased its stake in shares of NxStage Medical by 1.3% in the fourth quarter. Morgan Stanley now owns 67,174 shares of the medical device company’s stock worth $1,472,000 after buying an additional 874 shares during the period.

NxStage Medical, Inc is a medical device company. The Company is engaged in the development, manufacturing and marketing of products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. The Company’s products include the System One, Streamline Blood Tubing Sets and AV Fistula and Apheresis Needles.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.